Fenfluramine

(RS )-N -ethyl-1 -[3 - (trifluoromethyl ) phenyl] propan- 2-amine

• C12H16F3N ( fenfluramine )
• C12H16F3N HCl ( fenfluramine · hydrochloride)

• 458-24-2 [( RS)- fenfluramine ]
• 404-82-0 [( RS)- fenfluramine hydrochloride · ]
• 3239-44-9 [( S)- fenfluramine ]
• 3239-45-0 [( S)- fenfluramine · hydrochloride ]
• 37577-24-5 [(R) - fenfluramine ]
• 3616-78-2 [(R) - fenfluramine · hydrochloride ]
• 16105-77-4 [( ±)- fenfluramine · hydrochloride ]

A08AA02, A08AA04

Anorectics

• 231.26 g · mol -1 ( fenfluramine )
• 267.72 g.mol -1 ( fenfluramine · hydrochloride)

108-112 ° C ( 15.6 hPa)

Risk

Template: Infobox chemical / molecular formula search available

Fenfluramine is an anorectic ( appetite suppressant ), which is structurally related to amphetamine, but not psychostimulant accompanying effects has. It seems rather easy sedating and promotes fatigue.

Pharmacology

Dexfenfluramine and its principal active metabolite N- norfenfluramine acts as a serotonin releaser, thus increasing the ( extracellular ) serotonin levels. It acts next to a 5 -HT2C agonist. Both serve the purpose of therapy. Is held responsible for its side effects ( agonistic ) effect of 5- HT2B receptors, for example, can also be found in the heart.

Admission

The eutomer dextro - fenfluramine, dexfenfluramine short ( Redux ) was prepared by Interneuron Pharmaceuticals and marketed by Wyeth -Ayerst Laboratories. During the 1990s it was approved for several years by the U.S. Food and Drug Administration FDA for the purpose of weight reduction.

1997 were drawn because observed after long-term use of heart valve damage and pulmonary hypertension from circulation fenfluramine / dexfenfluramine. It is known from animal studies, that prolonged Applikationssdauer the risk of damaging the serotonin neurons in the brain.